FDA Approves Otsuka's Jynarque as First Treatment to Kidney Decline in Rapidy...

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Apr 25, 2018 at 9:52 AM.

  1. #1 cafead, Apr 25, 2018 at 9:52 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    33,039
    Likes Received:
    3
    via
    • ADPKD, the fourth leading cause of end-stage renal disease,1,2 is a progressively debilitating genetic disease characterized by the development of fluid-filled cysts in the kidneys
    • Data from two phase 3 clinical trials showed that Jynarque (tolvaptan) slowed kidney function decline in adults at risk of rapidly progressing ADPKD

    article source
     
    Quote

Reply to Thread